Alliances
Huawei and Philips announced a China cloud healthcare partnership that uses AI to deliver best diagnostic practices and monitoring in second tier China cities. The partnership combines Huawei’s IT capability with Phillips’ knowledge of diagnostic scanning devices.
Two weeks after securing more than $46M in financing, Visterra struck a deal worth up to $1B with startup Vir Biotech.
Alnylam and startup Vir Biotech inked a deal worth up to $1B for the development and marketing of RNAi therapies aimed at treating infectious diseases including HBV.
Eli Lilly has signed a collaboration deal with CureVac that could total up to $1.8B.
Takeda is jumping into the $40B market for NASH and other diseases of the liver with a $470M+ investment into HemoShear Therapeutics.
Suzhou’s Innovent Biologics will use a proprietary H2L2 transgenic mouse platform owned by Harbour Biomed of Shanghai to discover new mAbs.
Warp Drive Bio inked a strategic collaboration deal with Roche for up to $387M.
Halozyme’s Enhanze drug delivery technology just won it a $105 million upfront payment from Bristol-Myers Squibb.
PRESS RELEASES